Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study

Ahmad Al-Qudimat, Raed M. Al-Zoubi, Aksam A. Yassin, Mustafa Alwani, Omar M. Aboumarzouk, KhaledAIRumaihi, Raidh Talib and Abdulla AlAnsari

*Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar; ‡Department of Chemistry, Jordan University of Science and Technology, Irbid, Jordan; †Department of Surgery, Division of Urology/Andrology, Hamad Medical Corporation, Doha, Qatar; §Center of Medicine and Health Sciences, Dresden International University, Dresden, Germany; ¶School of Medicine, Jordan University of Science and Technology, Irbid, Jordan

ABSTRACT

Objectives: To report the association between testosterone treatment in hypogonadal men with hepatic steatosis, non-alcoholic fatty liver disease and cardiovascular disease (CVD).

Methods: A prospective study was conducted to assess the physiological and functional performance of the long-term effects of testosterone undecanoate treatment on hepatic steatosis in 496 hypogonadal men. Two groups were studied, the treatment group (T-group) of 312 patients treated with TU 1000 mg every 12 weeks and followed for 8 years, and an untreated control group (C-group) of 184 patients. We evaluated liver functions and Fatty Liver Index (FLI) according to Mayo Clinic parameters and guidelines.

Results: The T-group showed a decrease in the FLI (from a mean [SD] of 83.70 [12.15] to 67.12 [19.21]), bilirubin (from a mean [SD] of 1.69 [4.21] to 1.31 [1.91] mg/dL), triglycerides (from a mean [SD] of 254.87 [92.99] to 213.37 [66.91] mg/dL), and gamma-glutamyl-transferease (from a mean [SD] of 39.45 [11.51] to 29.11 [7.68] U/L) over the duration of the study. Other parameters were also reduced in the T-group such as body mass index (from a mean [SD] of 31.59 [4.51] to 29.50 [3.84] kg/m²) and waist circumference (from a mean [SD] of 107.51 [9.95] to 101.86 [9.28] cm). A total of 25 deaths (7.8%) were recorded in the T-group, among them, 11 (44%) were related to CVD. While in the C-group 28 deaths (15.2%) were recorded and all the reported deaths (100%) were related to CVD.

Conclusions: The findings suggest that long-term testosterone therapy in hypogonadal men improves liver function. While, the physiological and functional improvements in the liver may be associated with a decrease in CVD-related mortality.

Keywords
Testosterone therapy; renal function; men; hypogonadism; cardiovascular risk factor; mortality

Introduction

The prevalence of hepatic steatosis has substantially increased in the last decade and reached 10–24% worldwide, with a strong association with type II diabetes mellitus (T2DM) and obesity according to several studies, especially in Western societies [1].

The main characteristic of hepatic steatosis is the fat deposition in liver and is referred to as non-alcoholic fatty liver disease (NAFLD). NAFLD is a liver inflammation that can lead to cirrhosis, liver failure, and often hepatocarcinoma [2]. Hepatic steatosis is also associated with an increase incidence of metabolic syndrome (MetS), T2DM, and obesity, where the key components of these diseases include hyperinsulinaemia, dyslipidaemia, and insulin resistance [3,4]. The prevalence of NAFLD ranges from 50% to 75% in patients with T2DM and in obese patients from 80% to 90% [5–11].

Hepatic steatosis contributes to the increase in the risk of cardiovascular events amongst patients with T2DM (odds ratio 1.84) [12–15]. Moreover, the aetiology of hepatic steatosis and atherosclerosis are usually considered tissue-specific manifestations of the same cardiometabolic pathology [16]. MetS and T2DM are associated with low testosterone and considered factors for cardiovascular risk [17–19]. T2DM is ubiquitous in men associated with low testosterone levels and known to increase the risk of cardiovascular disease (CVD) [20,21].

Testosterone therapy (TTh) is the primary mainstay treatment for functional hypogonadism, in which it causes many symptoms such as impaired libido, erectile dysfunction, reduced quality of life, fatigue, and depression [22]. Several studies have reported that TTh reduces the risk of dyslipidaemia, insulin
resistance, improves glycaemic control and central obesity, and hence contributes to minimising the cardiovascular risk in hypogonadal men [22–31].

Although several reports on TTh have been published, the relationship between hepatic steatosis and testosterone is still limited. A few studies have reported a correlation between hepatic steatosis and low circulating serum testosterone levels [32–35], while others have shown no associations [36].

Völzke et al. [32] reported a retrospective study in men and showed a direct correlation between hepatic steatosis and a total testosterone (TT) level of ≤14.2 nmol/L, after excluding all confounding factors such as age, smoking, T2DM, body mass index (BMI), and visceral adipose tissue. Another study by Kim et al. [33] in healthy Korean men showed that low TT levels were inversely correlated with NAFLD after controlling for the effect of insulin resistance.

Supporting these clinical findings, the beneficial effects of testosterone on hepatic steatosis have been supported by numerous animal studies, as there is an elevation in hepatic lipid deposition in animal models with low testosterone levels [37–40]. TTh exhibited improvement of hepatic physiology on a molecular basis by altering expression of important hepatic regulatory genes [38]. It is thought that TTh improves steatohepatitis and hepatic steatosis by inhibiting macrovesicular lipid droplet formation, suppressing endoplasmic reticulum stress, and promoting very-low-density lipoprotein (LDL) export in castrated male rats [40].

Although clinical and experimental trials recommend a physiological level of testosterone to prevent hepatic steatosis in males, only a few studies have been published on the direct effects of long-term TTh on hepatic steatosis.

In the present study, we assessed the effect of long-term TTh on hepatic pathophysiology, by investigating hepatic steatosis and parameters of liver function in hypogonadal men over an 8-year period.

**Patients and methods**

In this prospective observational study, 496 older men (mean [SD] age 59 [9.5] years) were selected. The inclusion criteria were any symptomatic hypogonadal men with a testosterone level of ≤12.1 nmol/L. The exclusion criteria were patients who refused treatment or those with an absolute contraindication for testosterone treatment, e.g. active prostate cancer, male breast cancer, and polycythaemia.

Study settings were the Institute of Urology and Andrology, Segeberger Kliniken, Norderstedt-Hamburg, Germany, and the Men’s Health Department, Hamad Medical Cooperation, Doha, Qatar. The data collection started in 2004 November until January 2015. A total of 312 men were enrolled in the treatment group (T-group) and received 1000 mg testosterone undecanoate (TU) every 12 weeks, followed for 6 weeks and for up to 8 years (Figure 1). Among them, 140 men had discontinued treatment for 17 months after 5.5 years for reimbursement issues. The remaining 184 patients were selected for the control group (C-group). Both groups had similar baseline characteristics.

Every 6 months, we assessed the effect of long-term TU on hepatic steatosis by measuring the Fatty Liver Index (FLI). The FLI is a well-developed formula published by Bedogni et al. [41]. It is used for identifying

![Figure 1](image-url)  
*Figure 1*. Flow-chart of patient’s recruitment (T-group and C-group).
and predicting hepatic steatosis by including the following parameters: triglyceride, gamma-glutamyltransferase (γ-GT), BMI, and waist circumference (WC). All of them summed algorithmically in the following formula:

\[
FLI = \frac{e^{0.953 \times \text{log}_{e}(\text{triglycerides})} + 0.139 \times \text{BMI} + 0.718 \times \text{log}_{e}(\text{ggt}) + 0.053 \times WC - 15.745}{1 + e^{0.953 \times \text{log}_{e}(\text{triglycerides})} + 0.139 \times \text{BMI} + 0.718 \times \text{log}_{e}(\text{ggt}) + 0.053 \times WC - 15.745} 	imes 100
\]

Considering a FLI of <30 and ≥60 to rule out and rule in hepatic steatosis, respectively.

Other parameters of liver function, aspartate transaminase (AST), serum γ-GT, and alanine transaminase (ALT) were enzymatically evaluated using Abbott Alinity-C analytical system (Abbott Laboratories, Lake Bluff, IL, USA). A photometric colour test was used to access total bilirubin (Alinity C-Module; Abbott Laboratories).

The present study adhered to the ethical guidelines of the Declaration of Helsinki (1975) in addition to the approval by the German Ärztekammer (German Medical Association). All patients signed an informed consent before enrolling in the study.

**Statistical analysis**

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS®) version 12, (Windows package, IBM Corp., Armonk, NY, USA USA) and GraphPad Prism version 8.4.3 (GraphPad Software, La Jolla, CA, USA). Data were expressed as mean (± SD) or as a simple number. Clinical parameters were studied between both groups over the treatment period by linear mixed effects, repeated-measures model with period, group, and their interaction as fixed effects. Data were compared using the chi-squared test or Fisher’s exact test as appropriate. Correlations were performed using Spearman’s correlation coefficient. Regression was used for multivariate test analysis and a P < 0.05 was considered statistically significant.

**Results**

The characteristics of patients included in this study are described in **Table 1**. Significant differences were found between the T-group and C-group for BMI (P < 0.001), FLI (P < 0.001), triglycerides (P < 0.05), bilirubin (P < 0.05), and WC (P < 0.001). The mean (SD) age of the 312 patients in the T-group was 59 (9.5) years, whereas in 184 patients in the C-group it was 66.1 (7.6) years.

The TT levels increased in the hypogonadal men with TTh (T-group) during the first year of follow-up (from a mean [SD] of 7.81 [2.32] to 16.15 [1.98] nmol/L; P < 0.001) and compared to the C-group with a mean (SD) of 9.22 (3.41) to 9.33 (2.87) nmol/L, as shown in **Figure 2**.

The change in the FLI was also investigated between the two groups over the 8-year period. There was a decrease in the FLI in the T-group (from a mean [SD] of 83.70 [12.15] to 67.12 [19.21]) compared to the C-group, in which there was a clear increase in the FLI from a mean (SD) of 68.81 (19.27) to 81.48 (16.84), which was significant (P < 0.001) especially for years 3–8 (P < 0.001), as shown in **Figure 3**. There was no significant difference between the two groups in the second year.

**Figure 2.** The TT levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001).*

**Table 1.** Baseline characteristics of the T-group and C-group.

| Characteristic   | T-group | C-group | P       |
|-----------------|---------|---------|---------|
| N               | 312     | 184     |         |
| Mean (SD):      |         |         |         |
| Age, years      | 59 (9.5)| 66.1 (7.6)| <0.001 |
| Testosterone level, nmol/L | 7.81 (2.32) | 9.22 (3.41) | <0.001 |
| WC, cm          | 107.51 (9.95) | 100.76 (9.54) | <0.001 |
| Weight, kg      | 98 (12) | 92 (9)  | NS      |
| BMI, kg/m²      | 31.54 (4.51) | 29.50 (3.31) | <0.001 |
| FLI             | 83.70 (12.15) | 68.81 (19.27) | <0.001 |

NS, not statistically significant.
Figure 3. The FLI at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group. *significant; N.S., not significant.

Figure 4. The γ-GT levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001). N.S., not significant.

Figure 5. The bilirubin levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group. N.S., not significant.
The γ-GT levels dramatically dropped over the 8-year period in the T-group from a mean (SD) of 39.45 (11.51) to 29.11 (7.68) U/L ($P < 0.001$), whereas there was a steady increase in the γ-GT levels in the C-group, from a mean (SD) of 37.89 (29.61) to 39.68 (26.82) U/L ($P < 0.05$), as shown in Figure 4.

Bilirubin levels did not significantly change among the T-group patients (from a mean [SD] of 1.69 [4.21] to 1.31 [1.91] mg/dL; $P = 0.172$) and remained unmoved among the C-group patients (from a mean [SD] of 1.12 (7.11) to 1.24 (2.05) mg/dL; $P > 0.05$), as shown in Figure 5. It is worth noting that the bilirubin levels were elevated in the T-group at baseline ($P < 0.05$), which were reduced to comparable levels by 8-years compared to the C-group.

Furthermore, the AST levels were also found to be steady with baseline over the 8-year period for both groups, as shown in Figure 6. Although several fluctuations that were statistically significant occurred with AST during the study for the T-group. Significant results in AST were found for the C-group in the second and fourth years with $P < 0.05$ and $P < 0.05$, respectively.

The ALT levels declined slightly for both patient-groups but not significantly by the end of the study period, whereas levels increased in the T-group compared to the C-group in the third year and was found to be statistically significant in the first year of treatment ($P < 0.05$; Figure 7).

The triglyceride levels showed a decrease in the T-group over the 8-years (from a mean [SD] of 254.87 [92.99] to 213.37 [66.91] mg/dL), whereas it clearly increased in the C-group (from a mean [SD] of 196.38 [92.31] to 247.26 [62.39] mg/dL), as shown in Figure 8. Even though triglycerides continued to decline after the first year and up to 8 years. It continued to show

![Figure 6](image1.png)

**Figure 6.** The AST levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*$P < 0.001$). N.S., not significant.

![Figure 7](image2.png)

**Figure 7.** The ALT levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group. N.S., not significant.
a significant difference between both groups and up to 8 years ($P < 0.001$).

The BMI also showed a decrease in the T-group at 8 years (from a mean [SD] of 31.59 [4.51] to 29.50 [3.84] kg/m$^2$), whereas it clearly increased in the C-group (from a mean [SD] of 29.50 [3.31] to 31.20 [4.12] kg/m$^2$), as shown in Figure 9. Significant results for BMI between both groups were observed from 3 to 8 years.

The WC dropped significantly over the 8 years for the T-group (from a mean [SD] of 107.51 [9.95] to 101.86 [9.28] cm), whereas there was a steady increase in the C-group (from a mean [SD] of 100.76 [9.54] to 103.86 [8.38] cm; $P < 0.05$), as shown in Figure 10.

Furthermore, 28 deaths were recorded for the C-group (14.7%) compared to a lesser rate for the T-group (25 deaths, 7.8%, $P = 0.035$), in which most of the reported deaths from both groups were attributed to CVD (Table 2).

**Discussion**

Low testosterone levels in ageing men and the subsequent hypogonadism are associated with different complications such as MetS and the risk of CVD [3,4,42–44]. Additionally, liver steatosis is known to be symptomatic of metabolic dysfunction and could be considered as a hepatic indicator of MetS. Hepatic lipid deposition is independently associated with the low levels of testosterone in men [34]. Even though TTh improves CVD risk, and MetS and T2DM are well-documented [45–49], the long-term testosterone effects on hepatic steatosis are still limited. In the present study, we conducted an observational
Figure 10. The WC at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001).

Table 2. Comparison of adverse events between the T-group following long-term treatment with TU and the C-group.

| Adverse events | T-group | C-group | P     |
|---------------|--------|---------|-------|
| N             | 312    | 184     |       |
| Deaths, n (%) | 25 (7.8) | 28 (15.2) | 0.035 |
| Deaths due to CVD, n (%) | 11 (44%) | 28 (100) |
| Myocardial infarction | 5 (20) | 13 (48) |
| Stroke        | 2 (8)  | 7 (27)  |
| Heart failure | 2 (8)  | 3 (11)  |
| Aortic aneurysm | 1 (4) | 2 (7)   |
| Lung embolism | 1 (4)  | 2 (7)   |

*P < 0.001.

levels in hepatic steatosis in men. Another two studies in men with hepatic steatosis showed opposing results, the first one identified a strong association with low serum concentrations of testosterone, while the second study revealed no significant differences in testosterone levels compared to healthy men [35,36].

Most of the published studies investigating TTh in hypogonadism focussed on the association with sexual function restoration and improvements in metabolic parameters such as insulin resistance, glycaemic control, obesity, and lean muscle mass rather than the effect on hepatic steatosis and liver function.

Hoyos et al. [50] reported a study of 18 weeks of TTh in obese men with sleep apnea and showed an improvement in metabolic parameters such as insulin resistance and reduced liver fat, although there was no change in body weight overall. On the other hand, Magnussen et al. [51] recently reported a randomised controlled trial (RCT) of low testosterone levels in elderly men and revealed no effect on hepatic fat content as assessed by MRI or magnetic resonance spectroscopy following 6 months of TTh. Correspondingly, another randomised placebo-controlled trial reported by Dhindsa et al. [52] in 44 hypogonadal men with T2DM revealed no change in hepatic fat content following 6 months of TTh and assessed by MRI. Although these studies were doubtless well done, they had smaller cohorts and short-term treatment. In the present study, we present long-term liver function data of hypogonadal men with 8 years of TTh, with a rapid and continuous reduction in FLI during TTh. The present study suggests that long-term TTh improves liver function and reduces lipid accumulation in the liver up to 8 years.

The improvements in other components such as MetS and T2DM could also be mediated by TTh effects on hepatic steatosis [49,53]. The negative correlations
between hepatic steatosis and MetS or T2DM components such as insulin resistance, obesity, and dyslipidaemia were previously reported in the literature and supported our present hypothesis [6,54,55].

Moreover, the improvement in WC and BMI combined with the decrease in triglyceride levels in the T-group suggests an improvement in metabolic parameters compared to the C-group. It is well-documented that TTh reduces WC and BMI in hypogonadal men [56]. This improvement of metabolic parameters undoubtedly shows the beneficial long-term treatment effects of TTh on triglycerides and body composition in hypogonadal men that could improve liver steatosis and reduce cardiometabolic disorders and risk factors.

Evidence of the direct effect of testosterone on liver physiology was also reported in animal models [57–59]. It revealed a greater degree of hepatic steatosis and inflammation in hepatic androgen receptor (AR) knock-out mice [57], 5α-reductase type 1 knock-out mice [58] and testicular feminised mice with non-functional AR and low circulating testosterone levels [38]. Other reports showed a severe androgen deficiency in rodents induced by surgical orchidectomy and associated with hepatic steatosis in male mice and rats fed with a high-fat diet, where TTh was found to reduce the hepatic lipid deposition among these testosterone-deficient rodents [38,39].

The role of TTh in reducing expression of acetyl-CoA carboxylase α (Acaca), fatty acid synthase (Fasn) and sterol regulatory element-binding transcription factor 1 (Srebf1) genes involved in hepatic lipid assembly and secretion is well-established [37,38,59]. It has also been hypothesised that androgens could modulate liver fatty acid β-oxidation and lipid synthesis via regulation of SREBF-1 c, a key regulator of fatty acid synthesis, and its primary target gene stearoyl-CoA desaturase (SCD1) that catalyses the rate-limiting step in the synthesis monounsaturated fatty acids [57]. In addition to this hypothesis, orchidectomised rats were treated with dihydrotestosterone and an association was found with lower lipid accumulation by decreasing fatty acid, cholesterol synthesis, and increasing β-oxidation [60]. Nevertheless, these mechanistic have only recently arisen, and the validity of these findings from animal studies and the relationship between low testosterone levels and hepatic steatosis in humans requires further studies assessing biopsy samples in TTh clinical trials.

The reduction γ-GT and bilirubin levels in the T-group improved liver function by enhancing metabolic parameters. γ-GT, a glutathione catalase protein and the major thiol antioxidant, is associated with the presence of hepatic steatosis and an elevation in serum γ-GT is known as a marker of oxidative stress and correlates with the presence of CVD [61]. It plays a major role in LDL oxidation, apoptosis, platelet aggregation, and influences plaque rupture [62,63].

The association between elevated γ-GT with CVD and CVD-related mortality is also supported by many epidemiological studies [63–65].

Additionally, Traish et al. [66] reported the effects of TTh on MetS in 225 hypogonadal men and found a decline in AST and ALT levels over 5 years. We observed in our present study a moderate increase in ALT levels, exceeding those of AST at baseline in both groups, and usually observed in the biochemical pattern in hepatic steatosis. However, we report no significant change for AST and ALT levels following TTh treatment, with levels within the normal range for both groups. Other studies have reported a significant association with increasing risk of CVD in men with elevated AST/ALT ratio [67,68]. Others did not find any association [69] and suggest that γ-GT is the only biomarker associated with CVD [63].

The lower CVD-related deaths in the T-group is supported by other reports [70–73]. It is not certain whether the reduction in CVD-related deaths was due to the reduction in hepatic steatosis and improved liver function. Undeniably, patients having NAFLD have a high risk of evolving CVD, and the improvement of hepatic steatosis decreases the risk of CVD [16]. The improvement in hepatic steatosis enhances metabolic parameters and body composition, possibly resulting in the lower number of deaths in the T-group attributed to CVD.

Even though this observational study is not a RCT and has some limitations such as the direct comparison of testosterone vs non-treatment and the limiting scope of interpretation, the large patient cohort study, and the long-term follow-up of 8 years provide essential clinical data. It also evaluated the effectiveness and safety of long-term treatment with TU injections and a comparison to an untreated hypogonadal control group.

It is worth mentioning that liver parameters such as FLI, bilirubin, triglycerides, BMI, and WC were significantly higher among the T-group compared to the C-group at baseline. This indicates a selection bias as patients may have pre-existing disease while undergoing treatment.

As mentioned in our methodology, the large number of patients discontinuing TTh during the treatment course and hard to follow-up due to reimbursement issues, limited the group differences in liver function and explained some of the parameters in the T-group particularly, between 6 and 8 years.

**Conclusion**

The present study highlights that long-term TTh has beneficial effects on liver function in hypogonadal men with low levels of testosterone. As hepatic steatosis is known as a cardiometabolic risk factor, the present study also highlights the low CVD-related mortality rate with the improvement of liver function. Indeed,
placebo-controlled RCTs are still needed to elucidate the impact of TTh on hepatic function and steatosis in association with cardiovascular risk in hypogonadal men.

Acknowledgements

Open Access funding provided by the Qatar National Library.

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Ahmad Al-Qudimat http://orcid.org/0000-0003-1161-7244
M. Al-Zoubi http://orcid.org/0000-0002-0548-429X
Aksam A. Yassin http://orcid.org/0000-0001-5457-3443
Omar M. Aboumarzouk http://orcid.org/0000-0002-7961-7614
Abdulla Al Ansari http://orcid.org/0000-0002-6242-5667

References

[1] Barratt AS. Nonalcoholic fatty liver disease: epidemiology, assessments, and interventions entering 202. Clin Ther. 2021;43(3):436–437.
[2] Mohr BA, Bhasin S, Link CL, et al. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts male aging study. Eur J Endocrinol. 2006;155(3):443–452.
[3] Kuk J, Sex LS. Ethnic differences in the relationship between changes in anthropometric measurements and visceral fat in adolescents with obesity. J Pediatr. 2019;Oct;121:121–127.
[4] Grzesiak K, Ryl A, Ratajczak W, et al. Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia. Aging (Albany NY). 2019 Mar 13;11(5):1524–1536.
[5] Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2(6):335–348.
[6] Amin N, Gonzalez S, Purkal J, et al. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019 Nov 27;11(520).
[7] Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the dionysos study. Hepatology. 2007;46(5):1387–1391.
[8] Ballestreri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–944.
[9] Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019 Apr;156(5):1264–1281.e4.
[10] Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–161.
[11] Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–350.
[12] Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabetic Med. 2006;23(4):403–409.
[13] Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54(12):3541.
[14] Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30(8):2119.
[15] Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–1350.
[16] Wójcik-Cichy K, Koslińska-Berkan E, Piekar ska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepatol. 2018;4(1):1–6.
[17] Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496–503.
[18] Jones TH. Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome. J Diabetes. 2010;2(3):146–156.
[19] Trashi AM, Guay A, Feeley R, et al. The dark side of testosterone deficiency: i. Metabolic syndrome and erectile dysfunction. J Andrology. 2009;30(1):10–22.
[20] Daka B, Langer RD, Larsson CA, et al. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord. 2015;15:35.
[21] Hackett G. Type 2 diabetes and testosterone therapy. World J Mens Health. 2019;37(1):31–44.
[22] Almehmadi Y, Yassin AA, Nettleship JE, et al. Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. Arab J Urol. 2016;14(1):31–36.
[23] Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1):1–7.
[24] Kapoor D, Goodwin E, Chanher KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.
[25] Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Andrology. 2009;30(6):726–733.
[26] Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. 2010;142(1):50–55.
[27] El Meliegy A, Motawi A, El Salam MAA. Systematic review of hormone replacement therapy in the infertile man. Arab J Urol. 2018;16:140–147.

[28] Saad F, Yassine AA, Haider A, et al. Effects of testosterone on the lower urinary tract go beyond the prostate: new insights, new treatment options. Arab J Urol. 2011;9:147–152.

[29] Kalinchenko SY, Tishova YA, Ms Khalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73(5):602–612.

[30] Yassin AA, Saad F, Haider A, et al. The role of the urologist in the prevention and early detection of cardiovascular disease. Arab J Urol. 2011;9:57–62.

[31] Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–837.

[32] Völzke H, Aumann N, Krebs A, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl. 2010;33(1):45–53.

[33] Kim S, Kwon H, Park JH, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012;12:69.

[34] Barbonetti A, Caterina Vassallo MR, Cotugno M, et al. Low testosterone and non-alcoholic fatty liver disease: evidence for their independent association in men with chronic spinal cord injury. J Spinal Cord Med. 2016;39(4):443–449.

[35] Kley HK, Nieschlag E, Wiegelmann W, et al. Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis. Acta Endocrinol (Copenhagen). 1975;79(2):275–285.

[36] Mykng O, Aa vaag A, Digranes Ø. Androgen-oestrogen imbalance in men with chronic alcoholism and fatty liver. Alcohol. Alcoholol. 1987;22(1):7–15.

[37] Senmaru T, Fukui M, Okada H, et al. Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense LDL, and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet. Metabolism. 2013;62(6):851–860.

[38] Kelly DM, Nettleship JE, Akhtar S, et al. Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sci. 2014;109(2):95–103.

[39] Nikolaenko L, Jia Y, Wang C, et al. Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. Endocrinology. 2014;155(2):417–428.

[40] Jia Y, Yee JK, Wang C, et al. Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress. Am J Physiol Endocrinol Metab. 2017;314(4):E366–E376.

[41] Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33.

[42] Boden WE, Miller MG, McBride R, et al. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. Am Heart J. 2020;224:65–76.

[43] Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669–1675.

[44] Morgunov LV, Denisova IA, Rozhkova TI, et al. Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. Aging Male. 2020;23(1):71–80.

[45] Groti K, Żurán I, Antonić B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018;21(3):158–169.

[46] Salman M, Yassin DJ, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. Aging Male. 2017;20(1):45–48.

[47] Canguven O, Talib RA, El Ansari W, et al. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men. Andrologia. 2017;49:10.

[48] Saad F, Yassine A, Doros G, et al. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obesity. 2016;40(1):162–170. (2005).

[49] Yassin AA, Nettleship J, Almehmadi Y, et al. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia. 2016;48(7):793–799.

[50] Hoyos CM, Yee BJ, Phillips CL, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167(4):531–541.

[51] Magnussen LV, Andersen PE, Diaz A, et al. MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol. 2017;177(2):157.

[52] Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39(1):82–91.

[53] Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217(3):R25–45.

[54] Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708–2715.

[55] Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.

[56] Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16(7):581–606.
[57] Lin HY, Yu IC, Wang RS, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology. 2008;47(6):1924–1935.

[58] Dowman JK, Hopkins LJ, Reynolds GM, et al. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154 (12):4536–4547.

[59] Kelly DM, Akhtar S, Sellers DJ, et al. Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse. Endocrine. 2016;54 (2):504–515.

[60] Zhang H, Liu Y, Wang L, et al. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res. 2013;54 (2):345–357.

[61] Westerbacka J, Cornér A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47 (8):1360–1369.

[62] Emdin M, Pompella A, Gamma-Glutamyltransferase PA. Atherosclerosis, and cardiovascular disease. Circulation. 2005;112(14):2078–2080.

[63] Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010;13(1):36–41.

[64] Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4 (24):481.

[65] Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27 (1):127–133.

[66] Traish AM, Haider A, Doros G, et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68 (3):314–329.

[67] Weng SF, Kai J, Guha IN, et al. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart. 2015;2(1):e000272.

[68] Yokoyama M, Watanabe T, Otaki Y, et al. Association of the aspartate aminotransferase to alanine aminotransferase ratio with BNP level and cardiovascular mortality in the general population: the yamagata study 10-year follow-up. Dis Markers. 2016;2016:4857917.

[69] Choi KM, Han K, Park S, et al. Implication of liver enzymes on incident cardiovascular diseases and mortality: a nationwide population-based cohort study. Sci Rep. 2018;8(1):3764.

[70] Wallis CJ, Lo K, Lee Y, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4 (6):498–506.

[71] Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–327.

[72] Saad F, Yassin A, Almehmadi Y, et al. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports. Aging Male. 2015;18 (3):164–168.

[73] Yassin A, Netteship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64–69.